Curis Inc (CRIS) shareholders
Close on Nov 17, 2026Market cap $1.13MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) | 4,215,165 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 4,215,165 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Stonepine Capital, L.P. Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more | 4,025,992 | 9.90% | 13G (passive) | Mar 17, 2026 |
| Nantahala Capital Partners Limited Partnership | 2,944,000 | 6.98% | 13G (passive) | Mar 31, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 1,287,337 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Bleichroeder LP Joint filing with Bleichroeder Holdings LLC (9.90%), Andrew Gundlach (9.90%) | 1,035,662 | 9.90% | 13G (passive) | Mar 31, 2025 |
| Maverick Capital Management, LLC Joint filing with Maverick Capital, Ltd. (8.00%), Lee S. Ainslie III (8.00%) | 681,381 | 8.00% | 13G (passive) amendment | Dec 31, 2024 |
| Thomas A. Satterfield, Jr. | 616,565 | 8.80% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRIS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bleichroeder LP | 190,116 | 9.10% | $1.99M | – | 0.36% |
| Stonepine Capital Management, LLC | 165,609 | 7.92% | $1.73M | −20,711 | 0.98% |
| Nantahala Capital Management, LLC | 98,944 | 4.73% | $1.03M | −1,056 | 0.02% |
| Cable Car Capital, LP | 66,667 | 3.19% | $696.13K | – | 0.01% |
| CM Management, LLC | 27,500 | 1.32% | $287.16K | +20,000 | 0.19% |
| Morgan Stanley | 25,215 | 1.21% | $263.29K | +12,503 | 0.00% |
| Vanguard Capital Management LLC | 17,192 | 0.82% | $179.49K | −1,524 | 0.00% |
| Geode Capital Management, LLC | 14,655 | 0.70% | $153.04K | +6,239 | 0.00% |
| M28 Capital Management LP | 14,244 | 0.68% | $148.74K | – | 0.32% |
| Flputnam Investment Management Co | 12,288 | 0.59% | $128.31K | New | 0.00% |
| Renaissance Technologies LLC | 7,099 | 0.34% | $74.12K | −11,238 | 0.00% |
| XTX Topco Ltd | 5,408 | 0.26% | $56.47K | New | 0.00% |
| Sphera Funds Management Ltd. | 4,950 | 0.24% | $1.03M | −94,797 | 0.13% |
| Northern Trust Corp | 4,794 | 0.23% | $50.05K | +4,269 | 0.00% |
| Vanguard Fiduciary Trust Co | 3,083 | 0.15% | $32.19K | – | 0.00% |
| BlackRock, Inc. | 2,667 | 0.13% | $27.85K | −7 | 0.00% |
| Focused Wealth Management, Inc | 2,502 | 0.12% | $26.13K | −2,985 | 0.00% |
| Maverick Capital Ltd | 2,478 | 0.12% | $6.19K | – | 0.00% |
| Gsa Capital Partners Llp | 1,138 | 0.05% | $12.00K | New | 0.00% |
| State Street Corp | 1,052 | 0.05% | $10.99K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 37 | 1M | 32.1% | 7 / 5 | 10 / 11 | 0M | 0M |
| Q1 2026 | 42 | 1M | 37.7% | 11 / 12 | 6 / 9 | 1M | 0M |
| Q4 2025 | 41 | 0M | 10.4% | 5 / 7 | 10 / 5 | 0M | 0M |
| Q3 2025 | 41 | 0M | 11.0% | 4 / 13 | 5 / 5 | 0M | 0M |
| Q2 2025 | 42 | 0M | 10.3% | 5 / 7 | 7 / 3 | 0M | 0M |
| Q1 2025 | 40 | 0M | 11.2% | 5 / 6 | 10 / 4 | 0M | 0M |
| Q4 2024 | 40 | 0M | 7.7% | 10 / 14 | 3 / 2 | 0M | 0M |
| Q3 2024 | 32 | 0M | 4.8% | 4 / 5 | 6 / 5 | 0M | 0M |
| Q2 2024 | 34 | 0M | 5.5% | 2 / 12 | 5 / 4 | 0M | 0M |
| Q1 2024 | 36 | 0M | 5.0% | 5 / 9 | 5 / 7 | 0M | 0M |
| Q4 2023 | 38 | 0M | 5.6% | 8 / 8 | 9 / 5 | 0M | 0M |
| Q3 2023 | 35 | 0M | 5.1% | 34 / 0 | 1 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James E. Dentzer | President & CEO, Director | 148,730 | 7.12% | Jul 9, 2026 |
| Jonathan B. Zung | CDO | 66,667 | 3.19% | Jul 9, 2026 |
| Diantha Duvall | CFO | 77,707 | 3.72% | Jul 9, 2026 |
| Ahmed Hamdy MD | CMO | 66,667 | 3.19% | Mar 23, 2026 |
| John Hohneker | Director | – | – | Jul 9, 2026 |
| Martyn D. Greenacre | Director | 26,089 | 1.25% | Jul 9, 2026 |
| Kenneth I. Kaitin | Director | 11,407 | 0.55% | Jul 9, 2026 |
| Anne Elizabeth Borgman | Director | – | – | Jul 9, 2026 |
| Marc Rubin | Director | 28,108 | 1.34% | Jul 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kenneth I. Kaitin Director | Mar 31, 2026 | Buy | +10,000 | $0.55 | $5.50K | 11,407 |
| Jonathan B. Zung CDO | Mar 20, 2026 | Conversion | +66,667 | – | – | 66,667 |
| Ahmed Hamdy MD CMO | Mar 20, 2026 | Conversion | +66,667 | – | – | 66,667 |
| James E. Dentzer President & CEO, Director | Mar 20, 2026 | Conversion | +133,333 | – | – | 148,730 |
| Diantha Duvall CFO | Mar 20, 2026 | Conversion | +66,666 | – | – | 77,707 |
| Marc Rubin Director | Mar 20, 2026 | Conversion | +26,667 | – | – | 28,108 |
| James E. Dentzer President & CEO, Director | Jan 31, 2022 | Sale(10b5-1 plan) | −3,094 | $3.07 | $9.50K | 64,877 |
| James E. Dentzer President & CEO, Director | Jan 27, 2022 | Sale(10b5-1 plan) | −2,406 | $3.18 | $7.65K | 67,971 |
| James E. Dentzer President & CEO, Director | Jan 26, 2021 | Sale(10b5-1 plan) | −3,094 | $10.59 | $32.77K | 67,268 |
| James E. Dentzer President & CEO, Director | Jan 25, 2021 | Sale(10b5-1 plan) | −2,283 | $10.96 | $25.02K | 70,362 |
| James E. Dentzer President & CEO, Director | Jan 24, 2020 | Sale(10b5-1 plan) | −3,094 | $1.64 | $5.07K | 42,158 |
| James E. Dentzer President & CEO, Director | Jan 23, 2020 | Sale(10b5-1 plan) | −3,658 | $1.69 | $6.18K | 45,252 |
| James E. Dentzer President & CEO, Director | Jan 24, 2019 | Sale(10b5-1 plan) | −3,094 | $1.16 | $3.59K | 41,639 |
| Kenneth I. Kaitin Director | Jan 23, 2019 | Sale(10b5-1 plan) | −14,800 | $1.05 | $15.54K | 28,121 |
| Marc Rubin Director | Jan 23, 2019 | Sale(10b5-1 plan) | −18,500 | $1.05 | $19.43K | 28,819 |
| James E. Dentzer President & CEO, Director | Jan 23, 2019 | Sale(10b5-1 plan) | −2,397 | $1.09 | $2.61K | 44,733 |
| Robert Martell Head of Research & Development | Jan 23, 2019 | Sale(10b5-1 plan) | −5,500 | $1.07 | $5.89K | 23,027 |
| Robert Martell Head of Research & Development | Jan 23, 2019 | Tax withholding | −8,473 | $1.07 | $9.07K | 28,527 |
| Martyn D. Greenacre Director | Jan 23, 2019 | Sale(10b5-1 plan) | −18,500 | $1.05 | $19.43K | 26,089 |
| Lori Anne Kunkel Director | Jan 23, 2019 | Sale(10b5-1 plan) | −14,800 | $1.05 | $15.54K | 22,200 |
| Lori Anne Kunkel Director | Jan 22, 2018 | Award | +185,000 | – | – | 185,000 |
| Kenneth I. Kaitin Director | Jan 22, 2018 | Award | +185,000 | – | – | 214,607 |
| Marc Rubin Director | Jan 22, 2018 | Award | +185,000 | – | – | 236,596 |
| Robert Martell Director | Jan 22, 2018 | Award | +185,000 | – | – | 185,000 |
| James E. Dentzer Chief Financial Officer | Jan 22, 2018 | Award | +206,250 | – | – | 212,011 |
| Martyn D. Greenacre Director | Jan 22, 2018 | Award | +185,000 | – | – | 222,945 |
| Ali Ph.D. Fattaey President & CEO, Director | Jan 22, 2018 | Award | +206,250 | – | – | 322,140 |
| David Tuck Chief Medical Officer | Jan 22, 2018 | Award | +133,750 | – | – | 169,424 |
| Marc Rubin Director | Nov 16, 2017 | Buy | +25,000 | $0.98 | $24.50K | 51,596 |
| Ali Ph.D. Fattaey President & CEO, Director | Nov 15, 2017 | Buy | +50,000 | $1.06 | $53.00K | 115,890 |
| Kenneth I. Kaitin Director | May 31, 2017 | Tax withholding | −12,193 | $1.71 | $20.85K | 29,607 |
| Kenneth I. Kaitin Director | May 31, 2017 | Option exercise | +10,000 | $1.39 | $13.90K | 36,800 |
| Kenneth I. Kaitin Director | May 31, 2017 | Option exercise | +5,000 | $1.39 | $6.95K | 41,800 |
| Martyn D. Greenacre Director | May 31, 2017 | Tax withholding | −12,193 | $1.71 | $20.85K | 37,945 |
| Martyn D. Greenacre Director | May 31, 2017 | Option exercise | +5,000 | $1.39 | $6.95K | 50,138 |
| Martyn D. Greenacre Director | May 31, 2017 | Option exercise | +10,000 | $1.39 | $13.90K | 45,138 |
| James R. McNab Director | May 5, 2017 | Sale(10b5-1 plan) | −16,176 | $1.90 | $30.73K | 50,000 |
| James R. McNab Director | May 5, 2017 | Sale(10b5-1 plan) | −16,176 | $1.90 | $30.73K | 50,000 |
| James R. McNab Director | May 4, 2017 | Sale(10b5-1 plan) | −30,100 | $1.97 | $59.30K | 66,176 |
| James R. McNab Director | May 4, 2017 | Sale(10b5-1 plan) | −30,100 | $1.97 | $59.30K | 66,176 |
| James R. McNab Director | May 3, 2017 | Sale(10b5-1 plan) | −30,000 | $2.18 | $65.40K | 96,276 |
| James R. McNab Director | May 3, 2017 | Sale(10b5-1 plan) | −30,000 | $2.18 | $65.40K | 96,276 |
| James R. McNab Director | May 2, 2017 | Sale(10b5-1 plan) | −35,646 | $2.31 | $82.34K | 126,276 |
| James R. McNab Director | May 1, 2017 | Sale(10b5-1 plan) | −38,113 | $2.38 | $90.71K | 161,922 |
| James R. McNab Director | Apr 28, 2017 | Sale(10b5-1 plan) | −42,949 | $2.45 | $105.23K | 200,035 |
| James R. McNab Director | Apr 27, 2017 | Sale(10b5-1 plan) | −37,202 | $2.57 | $95.61K | 242,984 |
| James R. McNab Director | Apr 26, 2017 | Sale(10b5-1 plan) | −32,738 | $2.65 | $86.76K | 879,688 |
| James R. McNab Director | Apr 26, 2017 | Sale(10b5-1 plan) | −19,814 | $2.65 | $52.51K | 280,186 |
| James R. McNab Director | Apr 25, 2017 | Sale(10b5-1 plan) | −56,940 | $2.60 | $148.04K | 912,426 |
| James R. McNab Director | Apr 24, 2017 | Sale(10b5-1 plan) | −42,076 | $2.56 | $107.71K | 969,366 |
| James R. McNab Director | Apr 24, 2017 | Sale(10b5-1 plan) | −42,076 | $2.56 | $107.71K | 1,269,366 |
| James R. McNab Director | Apr 21, 2017 | Sale(10b5-1 plan) | −45,705 | $2.58 | $117.92K | 1,011,442 |
| James R. McNab Director | Apr 21, 2017 | Sale(10b5-1 plan) | −45,705 | $2.58 | $117.92K | 1,311,442 |
| James R. McNab Director | Apr 20, 2017 | Sale(10b5-1 plan) | −22,541 | $2.66 | $59.96K | 1,057,147 |
| James R. McNab Director | Apr 20, 2017 | Sale(10b5-1 plan) | −22,541 | $2.66 | $59.96K | 1,357,147 |
| Reddy's Holdings Ltd Dr. 10% owner | Sep 7, 2016 | Buy | +10,208,333 | $2.40 | $24.50M | 27,328,464 |
| Martyn D. Greenacre Director | May 27, 2016 | Sale | −5,000 | $1.69 | $8.45K | 35,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Option exercise | +5,000 | $1.67 | $8.35K | 40,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Option exercise | +10,000 | $1.67 | $16.70K | 45,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Sale | −10,000 | $1.69 | $16.90K | 35,183 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Curis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,962 shares on Sep 16, 2026 over the last 90 days.
See a number that looks wrong?